612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

Autor:	Xin Tong Li, Evan Y. Yu, Christophe Massard, G. Gravis, Peter C.C. Fong, Charles Schloss, Howard Gurney, Joan Carles, Josep M. Piulats, Tilman Todenhöfer, Luke T. Nordquist, B. Laguerre, Michael Paul Kolinsky, Ali Tafreshi, Michael Stoeckle, J.A. Arranz Arija, Christian Heinrich Poehlein, Marinela Augustin, J.S. de Bono, Stéphane Oudard
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty business.industry Hematology Pembrolizumab Castration resistant medicine.disease Olaparib Prostate cancer chemistry.chemical_compound Docetaxel chemistry Internal medicine Cohort medicine In patient business medicine.drug
Zdroj:	Annals of Oncology. 32:S652-S653
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.1125
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::74b8b10a1397d27dff94f162d1870bf4 https://doi.org/10.1016/j.annonc.2021.08.1125 Zobrazit plný text záznamu